EGFR and non-small cell lung carcinoma: Specifically, recent clinical trials for patients with advanced and EGFR-mutated NSCLC demonstrated objective response rates ranging from 63% to 80%, disease control rates of >90% and grade 3 or greater adverse events ranging from 9% to 50% as short-term outcomes [6–11].